Where to Inject Glucagon: Recommended Body Sites

Glucagon for severe hypoglycemia can be injected into three recommended body sites: the outer upper arm, the outer thigh, and the abdomen. These are the same general areas used for insulin and other subcutaneous injections, and all three raise blood sugar effectively. In an emergency, though, the practical question often matters more than the anatomical one, because the person giving the injection may be a panicked bystander rather than a trained clinician.

The Three Standard Injection Sites

Clinical trials of injectable glucagon products consistently use the same three body regions: the upper arm, the leg (specifically the outer thigh), and the abdomen.¹ Product labeling for glucagon emergency kits and autoinjectors reflects this same set of sites. For subcutaneous injection, the goal is to deliver glucagon into the fatty tissue just beneath the skin, and these three areas tend to have enough subcutaneous fat in most people to make that straightforward.

Each site has minor practical differences. The outer thigh offers a large, flat surface that is easy to reach, especially if you are injecting yourself. The abdomen provides a broad area with consistent subcutaneous tissue in most adults, though you should avoid the area immediately around the navel. The outer upper arm is often the most accessible site when someone else is giving the injection, because a sleeve can be pushed up quickly without fully undressing the person. None of these sites is categorically better than the others for glucagon absorption.

Does It Matter Whether the Injection Goes Subcutaneous or Intramuscular?

A common concern is whether you need to inject glucagon into the fat layer beneath the skin or deeper into the muscle. The short answer is that it does not make a meaningful difference to the outcome. A study comparing subcutaneous and intramuscular glucagon injection found that plasma glucagon levels rose rapidly by both routes, and the resulting blood glucose response was the same.² Ten minutes after injection, average plasma glucagon climbed to over 2,600 pg/mL by the intramuscular route and over 3,200 pg/mL by the subcutaneous route, but neither had a clinical advantage in terms of raising blood sugar.²

Intravenous glucagon does work faster, but that requires IV access and a healthcare setting. For anyone giving glucagon outside a hospital, the subcutaneous or intramuscular distinction is essentially irrelevant. This is reassuring because in a real emergency, the person administering the shot is rarely thinking about tissue depth. They are trying to get the drug in quickly, and the evidence says that whether the needle lands in fat or muscle, the glucagon will still do its job.

Injecting Through Clothing

In a severe hypoglycemic episode, the person may be unconscious or seizing, and removing clothing to find an injection site adds time and complexity. Whether you can simply inject through clothing is a practical question that researchers have directly tested. In usability studies of a glucagon autoinjector, injection through various types of clothing delivered the full dose in bench testing. However, because clothing thickness varies widely, which can affect how deep the needle penetrates, the labeling still instructs users to inject on exposed skin.³

This creates a tension between what the data show and what the label says. Bench testing succeeded through clothing, but from a risk-management standpoint, manufacturers recommend exposed skin because they cannot account for every fabric weight, denim thickness, or layered winter outfit. In a real crisis, if the person is wearing a thin T-shirt and you cannot easily expose the skin, the risk of not giving glucagon at all is almost certainly worse than the risk of a slightly shallower injection through fabric. But if you have a few extra seconds, pulling up a sleeve or pant leg to expose the outer arm or thigh is the labeled recommendation.

Why the Injection Site Is Often Not the Hardest Part

Qualitative research with patients, caregivers, and bystanders has found that the injection site itself is rarely what people worry about most. Instead, the barriers tend to be the needle, the multi-step preparation process, and the social awkwardness of partially undressing someone in a public setting. In interviews, caregivers and acquaintances of people with type 1 diabetes described glucagon injection as intimidating: finding an injection site meant either partially disrobing the person or injecting through clothing, and both options made bystanders uncomfortable.⁴

Traditional glucagon emergency kits require mixing a powder with a diluent before injection, which adds steps and opportunities for error under pressure. This preparation complexity, more than the anatomical question of where to inject, is what causes the most hesitation. Many interview participants said they would prefer a nasal delivery option specifically because it eliminated the need to find an injection site, handle a needle, or remove clothing.⁴ One caregiver put it bluntly: with nasal glucagon, “I don’t have to get through clothes and stuff to do it.”

Understanding this context is important because it suggests that the best site for a glucagon injection is, in a very real sense, whichever site lets the bystander act fastest and most confidently. If the outer thigh is exposed and the person giving the injection feels comfortable targeting it, that is the best site for that moment. If the upper arm is more accessible, go with the upper arm. Hesitating to find the “perfect” site costs time that a severely hypoglycemic person does not have.

Newer Delivery Options That Bypass the Injection Site Question Entirely

The landscape of glucagon delivery has shifted considerably over the past several years. Nasal glucagon, which is a dry powder puffed into one nostril, was specifically developed to remove the injection barrier. It requires no mixing, no needle, no site selection, and no removal of clothing. For bystanders without medical training, it dramatically simplifies the rescue process.

Ready-to-use liquid glucagon autoinjectors have also reached the market. These devices come pre-mixed and deliver a subcutaneous injection with a mechanism similar to an epinephrine auto-injector: you press it against the skin and activate it. In clinical trials, these autoinjectors were administered to the upper arm, leg, or abdomen and were shown to be non-inferior to traditional emergency kits in restoring blood sugar.¹ The advantage of these devices is not that they change which body site you target, but that they reduce the number of steps between recognizing the emergency and completing the injection.

If you or someone you care for carries glucagon, the choice of device often has more practical impact than the choice of injection site. Nasal glucagon and autoinjectors have higher success rates in simulated emergencies, largely because untrained users can figure them out faster. The three standard body sites remain the same for any injectable form, but the barriers to actually completing an injection are lower with newer devices.

What Happens at the Injection Site After You Give Glucagon

Glucagon has a direct local effect on the tissue where it is injected. Research measuring blood flow at subcutaneous injection sites on the abdomen found that even a small dose of glucagon significantly increased local blood flow compared to baseline, an effect that persisted for at least 35 minutes after injection.⁵ This increased blood flow could theoretically speed the absorption of glucagon or other drugs injected nearby, though the primary clinical significance of this finding is still being explored.

In practical terms, some redness, warmth, or minor swelling at the injection site is normal after a glucagon injection. Nausea and sometimes vomiting are the most commonly reported side effects, but those are systemic reactions to the glucagon itself, not to the injection site. The site-specific effects tend to be mild and short-lived. If you have given someone glucagon and notice localized swelling or redness, that is expected and not a sign that the injection was done incorrectly.

Site Selection for Children and Smaller Body Types

The three recommended sites apply to children as well as adults, but body composition matters. A young child has less subcutaneous fat on the abdomen and upper arm than an adult, which means the outer thigh is often the easiest and most reliable site for pediatric glucagon injections. The thigh has a relatively large surface area even in small children and is straightforward to access, especially if the child is lying down.

For very lean adults or older children, the same principle applies: choose the site where you can most easily pinch a fold of skin and subcutaneous tissue. If the person is very thin, avoid areas where the needle could hit bone or go intramuscular in a way that is painful, though as noted earlier, intramuscular injection is still effective. The dose of glucagon may differ for children under a certain weight (many product labels recommend a half dose for children under about 25 kg or 55 lbs), but the injection sites remain the same three locations.

Glucagon After Exercise

An interesting and less widely known finding is that the body’s glucose response to glucagon varies depending on physical activity. In people with type 1 diabetes using insulin pumps, a low dose of glucagon produced a bigger blood-sugar rise after cycling compared to after resting.⁶ The average peak glucose increase was roughly 45% higher post-exercise than post-rest.

This matters for a scenario that many people with type 1 diabetes know well: exercise-induced hypoglycemia. If blood sugar drops during or after a workout, glucagon is likely to work at least as well as it would at rest, and possibly better. The injection site itself does not change based on whether the person has been exercising, but knowing that glucagon remains effective in this context is reassuring. Some researchers are exploring whether small “mini-doses” of glucagon given subcutaneously could be used proactively around exercise to prevent hypoglycemia rather than just treat it, though this is not yet standard practice.

Common Mistakes When Giving a Glucagon Injection

The errors that matter most in a glucagon emergency are rarely about site selection. They tend to fall into a few categories:

Incomplete mixing: With traditional powder-and-diluent kits, failing to fully dissolve the powder before injecting is a common mistake. If the solution looks cloudy or has visible particles, it needs more mixing. This problem does not apply to pre-mixed liquid glucagon products.
Partial dose delivery: In stress, people sometimes pull the needle out before the full dose is delivered, especially with a syringe. Autoinjectors reduce this risk by automating the injection.
Delay from overthinking site choice: Spending time trying to find the “right” spot, or debating whether to inject through clothing, when the person is unconscious and every minute matters. Any of the three standard sites is fine. Pick the one you can reach and go.
Injecting into scar tissue or heavily scarred skin: Absorption may be unpredictable in areas with significant scarring. If the person has had repeated injections in one area and the tissue feels lumpy or hardened, choose a different site.

The usability study of glucagon autoinjectors found that in simulated emergencies, injection-through-clothing was the type of error that labeling could successfully prevent: once people read the instructions, they followed them.³ The lesson is that reading the instructions before an emergency happens, when you are calm and can absorb the steps, dramatically improves performance under pressure. If you carry glucagon or live with someone who might need it, open the kit now and walk through the steps at least once. Choosing an injection site takes two seconds when you have already thought about it; it takes much longer when you are panicking and reading directions for the first time.

Rotation and Repeated Use

Glucagon is not a medication most people inject daily. It is a rescue drug, and many people go months or years between uses. Site rotation, which is a familiar concept for daily insulin users, is less of a concern with glucagon simply because the injections are so infrequent. However, if someone experiences repeated severe hypoglycemic episodes in a short time, it is reasonable to vary the injection site to avoid injecting into already-irritated tissue.

People who use insulin should be aware that their insulin injection sites and their glucagon injection sites overlap. If they have developed areas of lipohypertrophy (lumpy, hardened fatty tissue) from repeated insulin injections, those areas should be avoided for glucagon as well. The tissue changes in lipohypertrophic areas can make drug absorption erratic. Choosing a spot with normal-feeling skin ensures the glucagon gets absorbed predictably when it is needed most.